Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease - Takeaways - MDSpire

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

  • By

  • Katie Binley, PhD

  • May 1, 2026

  • 3 min

Share

  • 1

    Ikarovec is developing dual-pathway gene therapies for retinal degenerative diseases using a bicistronic gene therapy platform.

  • 2

    The lead program, IKAR-001, targets geographic atrophy by co-expressing PEDF for neuroprotection and soluble CD46 for complement modulation.

  • 3

    Current single-pathway therapies for geographic atrophy show modest effects and inconsistent improvements in visual function.

  • 4

    Neuroprotection is critical for meaningful outcomes in geographic atrophy, as it addresses neurodegeneration directly.

  • 5

    Ikarovec's gene therapy aims to provide both anatomical and functional benefits, representing a next-generation treatment for retinal diseases.

Original Source(s)

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

  • by Katie Binley, PhD

  • May 1, 2026

Related Content

The New Rules of Retina Drug Development

In a panel at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report